Skip to main content

Table 5 Drug utilization of HAM-net-registered patients

From: Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan

   Before the initial interview (n = 486) At the time of the initial interview (n = 486) In a year until the 2nd-year interview (n = 434) In a year until the 3rd-year interview (n = 370) In a year until the 4th-year interview (n = 304) In a year until the 5th-year interview (n = 257)
Oral steroid therapy (+) 326 (67.1%) 203 (41.8%) 209 (48.2%) 186 (50.3%) 154 (50.7%) 124 (48.2%)
(−) 134 (27.6%) 257 (52.9%) 214 (49.3%) 182 (49.2%) 148 (48.7%) 130 (50.6%)
unknown 26 (5.3%) 26 (5.3%) 11 (2.5%) 2 (0.5%) 2 (0.7%) 3 (1.2%)
Methyl-
prednisolone pulse therapy
(+) 191 (39.3%) 7 (1.4%) 33 (7.6%) 21 (5.7%) 11 (3.6%) 10 (3.9%)
(−) 267 (54.9%) 449 (92.4%) 391 (90.1%) 346 (93.5%) 292 (96.1%) 244 (94.9%)
unknown 28 (5.8%) 30 (6.2%) 10 (2.3%) 3 (0.8%) 1 (0.3%) 3 (1.2%)
Interferon-α treatment (+) 170 (35.0%) 14 (2.9%) 15 (3.5%) 12 (3.2%) 8 (2.6%) 8 (3.1%)
(−) 295 (60.7%) 448 (92.2%) 410 (94.5%) 356 (96.2%) 295 (97.0%) 247 (96.1%)
unknown 21 (4.3%) 24 (4.9%) 9 (2.1%) 2 (0.5%) 1 (0.3%) 2 (0.8%)